Company / Capital Expenditures
Xilio Therapeutics, Inc. Capital Expenditures History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$36.0K
FY2025
5-year range
$36.0K / $486.0K
FY2024-FY2025
Trend
-92.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$36,000 in FY2025.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures decreased 92.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.71 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.0K | -92.6% |
| FY2024 | $486.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026